Search
Position of EHA on Personalized Medicine
The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…
YoungEHA Mentorship Mixer at EHA2024
Hosted by the YoungEHA Committee, the Mentorship Mixer is a pilot event for a potential EHA mentorship program.
Read moreFundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
Healthy subjects frequently report minor bleedings that are frequently ‘background noise’ of normality rather than a true disorder. Nevertheless, unexpected or unusual bleeding may be alarming.
Read moreA new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.
Read moreSpecialized Working Groups
EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.
Read moreEnabling the spread of good research – a day in the life of an Editor-in-Chief
Most conversations with the Editor of a scientific journal usually revolve around the acceptance (hooray!) or rejection (oh no!) of our research work.
Read moreKite and Gilead @EHA25 Virtual
We are proud to support the first ever EHA25 Virtual congress. Please join us & leading experts to learn about the latest in cell therapies and COVID-19.
Read moreAddition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read more